 |
 |
 |
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
|
FOR IMMEDIATE RELEASE |
Media
Inquiries: |
The U.S. Food and Drug Administration and BG Medicine, a Massachusetts-based
biotechnology research company, have agreed to collaborate on a project designed
to overcome one of the obstacles to efficient development of safe drugs.
The Liver Toxicology Biomarker Study (LTBS), to be conducted under a Cooperative
Research and Development Agreement (CRADA) between the FDA's National Center
for Toxicological Research (NCTR) and the pharmaceutical industry, aims to
discover signs of human liver toxicity in a standard test used in the initial
stages of drug development. Early detection of potential safety problems is
one of the main objectives of the FDA's Critical Path Initiative, which seeks
to modernize drug development by making the process more predictable and successful,
and less costly.
"Liver toxicity is a common reason for drug development failure," said Dr. Janet Woodcock, FDA's Deputy Commissioner for Operations and the principal author of FDA's March, 2004 report, Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products.
"In part, this is due to the fact that the safety evaluation relies on decades-old technologies that may recognize safety problems only after extensive clinical studies. By identifying biomarkers for liver toxicity at the start of the development process, this research should yield important benefits for industry, the FDA, and the public."
The CRADA procedure routinely governs FDA's collaborative studies with the private sector. The LTBS has been designed by FDA and BG Medicine with input from other pharmaceutical companies and will be conducted, with their collaboration, at the NCTR laboratory in Jefferson, Ark. and BG Medicine in Waltham, Mass. Participating companies will receive access to all project data and a perpetual license to any discovered biomarkers.
####
RSS Feed for FDA News Releases [what's this?]
Get
free weekly updates about FDA press releases, recalls, speeches, testimony
and more.